Evidence map›Paper›PMID 33397362›Full record

ArticleJournal of biomedical science2021

O6-methylguanine-DNA methyltransferase modulates cisplatin-induced DNA double-strand breaks by targeting the homologous recombination pathway in nasopharyngeal carcinoma.

Shang-Hung Chen, Wen-Tsung Huang, Wan-Chen Kao, Sheng-Yen Hsiao, Hsin-Yi Pan, Chin-Wen Fang, Yow-Ling Shiue, Chia-Lin Chou, Chien-Feng Li

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomedical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Shang-Hung ChenNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Wen-Tsung HuangDivision of Hematology-Oncology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan.
Wan-Chen KaoDivision of Hematology-Oncology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan.
Sheng-Yen HsiaoDivision of Hematology-Oncology, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan.
Hsin-Yi PanNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Chin-Wen FangNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Yow-Ling ShiueInstitute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan.
Chia-Lin ChouInstitute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan. clchou3@gmail.com.
Chien-Feng LiNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. angelo.p@yahoo.com.tw.
Chi Mei Medical Center · TWNational Health Research Institutes · TWNational Sun Yat-sen University · TW

Funding

Chi Mei Medical Center, Liouying CLFHR10821Health Promotion Administration, Ministry of Health and Welfare MOHW109-TDU-B-212-134020, WanFang Hospital, Chi Mei Medical Center, and Hualien Tzu-Chi Hospital Joing Cancer Center Grant-Focus on Colon Cancer ResearchMinistry of Science and Technology, Taiwan MOST 104-2314-B-384-010 and MOST 104-2314-B-400-026National Health Research Institutes CA-106-PP-41
6 · The paper itself

Abstract

backgroundThe homologous recombination (HR) pathway is involved in DNA damage response (DDR), which is crucial to cancer cell survival after treatment with DNA damage agents. O6-methylguanine DNA methyltransferase (MGMT) is associated with cisplatin (CDDP) resistance in cancer cells; however, the underlying mechanisms remain unclear. Here, we explored the interactions between MGMT and the HR pathway in CDDP-activated DDR and their clinical implications in nasopharyngeal carcinoma (NPC).

methodsHuman NPC cells were assessed using loss-of-function approaches in vitro. The expression correlations between MGMT and major proteins of the HR pathway were analyzed through Western blotting, quantitative real-time PCR, and bioinformatic analysis by using a public database. The physical interactions between MGMT and HR proteins were studied using co-immunoprecipitation and immunofluorescence analyses. Cell comet tails and γ-H2AX expression levels were examined to evaluate double-strand break (DSB) formation. Established immunofluorescence and reporter analyses were conducted to measure HR activity. Xenograft and cell viability studies were used to assess the therapeutic potential of MGMT inhibition in combination with CDDP and poly(ADP-ribose) polymerase (PARP) inhibitor, respectively.

resultsAmong major proteins of the HR pathway, MGMT suppression inhibited CDDP-induced RAD51 expression. Bioinformatic analyses showed a positive correlation between MGMT and RAD51 expression in patients with NPC. Moreover, MGMT physically interacted with BRCA1 and regulated CDDP-induced BRCA1 phosphorylation (ser 988). In functional assays, MGMT inhibition increased CDDP-induced DSB formation through attenuation of HR activity. NPC xenograft studies demonstrated that MGMT inhibition combined with CDDP treatment reduced tumor size and downregulated RAD51 expression and BRCA1 phosphorylation. Furthermore, MGMT suppression increased PARP inhibitor-induced cell death and DSB formation in NPC cells.

conclusionMGMT is crucial in the activation of the HR pathway and regulates DDR in NPC cells treated with CDDP and PARP inhibitor. Thus, MGMT is a promising therapeutic target for cancer treatments involving HR-associated DDR.

Indexed as

DNA Breaks, Double-StrandedHomologous RecombinationAntineoplastic AgentsCell Line, TumorCisplatinDNADNA DamageGuanineHumansMethyltransferasesNasopharyngeal CarcinomaNasopharyngeal NeoplasmsAntineoplastic AgentsCisplatinDNAGuanineMethyltransferasesO-(6)-methylguanineCisplatinHomologous recombinationMGMTNasopharyngeal carcinomaPARP inhibitor

Identifiers

PMID33397362
PMCPMC7780675
OpenAlexW3119666313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.